Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ELOS's Cash to Debt is ranked higher than
93% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. ELOS: No Debt )
ELOS' s 10-Year Cash to Debt Range
Min: 65.7   Max: No Debt
Current: No Debt

Equity to Asset 0.76
ELOS's Equity to Asset is ranked higher than
80% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ELOS: 0.76 )
ELOS' s 10-Year Equity to Asset Range
Min: 0.61   Max: 0.89
Current: 0.76

0.61
0.89
F-Score: 3
Z-Score: 4.21
M-Score: -1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -2.38
ELOS's Operating margin (%) is ranked higher than
60% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. ELOS: -2.38 )
ELOS' s 10-Year Operating margin (%) Range
Min: -249.56   Max: 44.31
Current: -2.38

-249.56
44.31
Net-margin (%) 0.64
ELOS's Net-margin (%) is ranked higher than
64% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. ELOS: 0.64 )
ELOS' s 10-Year Net-margin (%) Range
Min: -243.89   Max: 47.2
Current: 0.64

-243.89
47.2
ROE (%) 0.71
ELOS's ROE (%) is ranked higher than
64% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. ELOS: 0.71 )
ELOS' s 10-Year ROE (%) Range
Min: -81.65   Max: 63.9
Current: 0.71

-81.65
63.9
ROA (%) 0.54
ELOS's ROA (%) is ranked higher than
65% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. ELOS: 0.54 )
ELOS' s 10-Year ROA (%) Range
Min: -169.31   Max: 31.81
Current: 0.54

-169.31
31.81
ROC (Joel Greenblatt) (%) -12.35
ELOS's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. ELOS: -12.35 )
ELOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -833.83   Max: 1563.1
Current: -12.35

-833.83
1563.1
Revenue Growth (%) 8.80
ELOS's Revenue Growth (%) is ranked higher than
82% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ELOS: 8.80 )
ELOS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 188.4
Current: 8.8

0
188.4
» ELOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ELOS Guru Trades in Q2 2013

Charles Brandes 1,538,349 sh (+7.78%)
Jim Simons 705,580 sh (+6.21%)
Seth Klarman 4,000,000 sh (unchged)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 1,191,059 sh (-2.46%)
» More
Q3 2013

ELOS Guru Trades in Q3 2013

Charles Brandes 1,765,018 sh (+14.73%)
Chuck Royce 1,191,059 sh (unchged)
Seth Klarman 4,000,000 sh (unchged)
Mario Gabelli 24,000 sh (unchged)
Jim Simons 632,806 sh (-10.31%)
» More
Q4 2013

ELOS Guru Trades in Q4 2013

Charles Brandes 2,164,137 sh (+22.61%)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 1,191,059 sh (unchged)
Seth Klarman 4,000,000 sh (unchged)
Jim Simons 618,180 sh (-2.31%)
» More
Q1 2014

ELOS Guru Trades in Q1 2014

Steven Cohen 85,000 sh (New)
Mario Gabelli 24,000 sh (unchged)
Seth Klarman 4,000,000 sh (unchged)
Jim Simons 586,380 sh (-5.14%)
Chuck Royce 1,047,159 sh (-12.08%)
Charles Brandes 1,574,870 sh (-27.23%)
» More
» Details

Insider Trades

Latest Guru Trades with ELOS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-03-31 Reduce -27.23%0.09%$11.08 - $13.11 $ 10.05-15%1574870
Charles Brandes 2013-12-31 Add 22.61%0.06%$8.68 - $12.34 $ 10.05-3%2164137
Seth Klarman 2011-06-30 Add 155.74%1.18%$11.09 - $13.92 $ 10.05-19%3836071
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 143.80
ELOS's P/E(ttm) is ranked higher than
68% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 67.30 vs. ELOS: 143.80 )
ELOS' s 10-Year P/E(ttm) Range
Min: 6.81   Max: 776.25
Current: 143.8

6.81
776.25
P/B 1.60
ELOS's P/B is ranked higher than
86% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ELOS: 1.60 )
ELOS' s 10-Year P/B Range
Min: 0.58   Max: 10.37
Current: 1.6

0.58
10.37
P/S 1.40
ELOS's P/S is ranked higher than
82% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. ELOS: 1.40 )
ELOS' s 10-Year P/S Range
Min: 1.08   Max: 15.69
Current: 1.4

1.08
15.69
EV-to-EBIT -68.34
ELOS's EV-to-EBIT is ranked higher than
57% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. ELOS: -68.34 )
ELOS' s 10-Year EV-to-EBIT Range
Min: 2.3   Max: 46.9
Current: -68.34

2.3
46.9
Current Ratio 3.12
ELOS's Current Ratio is ranked higher than
72% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ELOS: 3.12 )
ELOS' s 10-Year Current Ratio Range
Min: 2.63   Max: 10.72
Current: 3.12

2.63
10.72
Quick Ratio 2.46
ELOS's Quick Ratio is ranked higher than
74% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. ELOS: 2.46 )
ELOS' s 10-Year Quick Ratio Range
Min: 2.07   Max: 10.39
Current: 2.46

2.07
10.39

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 5.70
ELOS's Price/Net Current Asset Value is ranked higher than
93% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ELOS: 5.70 )
ELOS' s 10-Year Price/Net Current Asset Value Range
Min: 0.91   Max: 10.14
Current: 5.7

0.91
10.14
Price/Tangible Book 2.10
ELOS's Price/Tangible Book is ranked higher than
88% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 6.18 vs. ELOS: 2.10 )
ELOS' s 10-Year Price/Tangible Book Range
Min: 0.71   Max: 9.33
Current: 2.1

0.71
9.33
Price/Median PS Value 0.50
ELOS's Price/Median PS Value is ranked higher than
97% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. ELOS: 0.50 )
ELOS' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 5.02
Current: 0.5

0.41
5.02
Price/Graham Number 3.40
ELOS's Price/Graham Number is ranked higher than
78% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 8.75 vs. ELOS: 3.40 )
ELOS' s 10-Year Price/Graham Number Range
Min: 0.93   Max: 12.51
Current: 3.4

0.93
12.51
Earnings Yield (Greenblatt) 10.60
ELOS's Earnings Yield (Greenblatt) is ranked higher than
91% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. ELOS: 10.60 )
ELOS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 43.6
Current: 10.6

2.1
43.6
Forward Rate of Return (Yacktman) -2.90
ELOS's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ELOS: -2.90 )
ELOS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 5.9   Max: 8.8
Current: -2.9

5.9
8.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:FGD.Germany
Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets innovative aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company's products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and one minimally invasive product for laser-assisted lipolysis. ELOS provides performance advantages over existing technologies that rely solely on optical energy. The Company's proprietary ELOS technology, which combines optical and electrical energy, enhances the user's ability to accurately target the tissue to be treated and enables real-time measurement of skin temperature, resulting in increased patient safety and comfort and improved treatment results. It now also offers in connection with the purchases of new VelaShape II, LipoLite and eMatrix devices, the Syneron Advantage program which enables physicians to gain access to its facial applications and body shaping technologies at a more affordable price point that are easier to finance in the current economic environment. As of March 1, 2013, its patent portfolio (including patents held by subsidiaries) consisted of 99 issued U.S. patents, and 112 patents applications pending in the U.S. (with an additional 392 applications pending internationally and 112 international patents), related to 180 patent families relating to its technology and products Its products compete against conventional non-light-based treatments, including Botox (neurotoxins) and collagen injections, sclerotherapy, electrolysis, liposuction, chemical peels and microdermabrasion. The Company's products are subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, as well as other regulatory bodies.
» More Articles for NAS:ELOS

Headlines

Articles On GuruFocus.com
comment on ELOS Jan 31 2012 
note on ELOS Oct 08 2011 
Why Is Seth Klarman Loading Up on Syneron Medical? Aug 29 2011 
comment on ELOS Aug 20 2011 
comment on ELOS Aug 20 2011 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman More Than Doubles Holdings in Syneron Medical Jul 12 2011 
Top Seth Klarman Holding, ELOS Rockets Up 20% Feb 16 2011 
Baupost’s Seth Klarman Buys Enzon Inc., Viasat Inc., Sells Horizon Lines Inc., News Corp., PDL Bio Nov 12 2009 
Magic Formula Moves, 4.23.08 Apr 23 2008 

More From Other Websites
Syneron Receives China CFDA Clearance for elure™ Advanced Skin Brightening Lotion Jul 22 2014
Syneron Receives China CFDA Clearance for elure™ Advanced Skin Brightening Lotion Jul 21 2014
Syneron Medical to Report Second Quarter 2014 Financial Results on August 6, 2014 Jul 18 2014
Syneron (ELOS): Moving Average Crossover Alert Jul 02 2014
Syneron Medical to Present at Jefferies 2014 Global Healthcare Conference May 30 2014
Syneron Medical's (ELOS) CEO Amit Meridor on Q1 2014 Results - Earnings Call Transcript May 14 2014
Q1 2014 Syneron Medical Ltd Earnings Release - Before Market Open May 14 2014
Syneron Medical reports Q1 adjusted EPS 4c, consensus 4c May 14 2014
Syneron Reports First Quarter 2014 Results May 14 2014
Fat-Destroying Machine Doubted by Stock Traders May 06 2014
Syneron Candela Achieves Approval to Market Its ALEX II System in Japan For Treatment of Benign... Apr 28 2014
Syneron Medical to Report First Quarter 2014 Financial Results on May 14, 2014 Apr 24 2014
Syneron Medical to Report First Quarter 2014 Financial Results on May 14, 2014 Apr 24 2014
Syneron Medical's CEO Discusses FDA Clearance of the UltraShape System - Conference Call Transcript Apr 17 2014
Syneron to Host Conference Call and Webcast to Discuss UltraShape FDA Clearance Apr 16 2014
A new roadmap: Equinox Blueprint provides vision for 21st century education Apr 16 2014
Syneron Receives US FDA Clearance to Market the UltraShape System for Fat Cell Destruction Apr 16 2014
The New Wave in Covidien's Endoscopic Devices Apr 15 2014
Syneron Medical receives FDA clearance to market UltraShape System Apr 14 2014
Syneron Receives US FDA Clearance to Market the UltraShape System for Fat Cell Destruction Apr 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide